Compare CNNE & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNNE | DCTH |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 686.6M | 578.4M |
| IPO Year | 2017 | 2015 |
| Metric | CNNE | DCTH |
|---|---|---|
| Price | $15.42 | $15.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $20.25 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 455.8K | 421.1K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.47% | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | ★ 0.12 | 0.04 |
| Revenue | ★ $499,700,000.00 | N/A |
| Revenue This Year | N/A | $24.54 |
| Revenue Next Year | N/A | $33.15 |
| P/E Ratio | ★ $130.08 | $399.50 |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $10.46 | $8.12 |
| 52 Week High | $19.88 | $17.42 |
| Indicator | CNNE | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 50.43 |
| Support Level | $14.04 | $9.98 |
| Resistance Level | $16.41 | $17.42 |
| Average True Range (ATR) | 0.42 | 0.41 |
| MACD | -0.03 | -0.24 |
| Stochastic Oscillator | 15.79 | 12.24 |
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.